EDP-938 for Respiratory Syncytial Virus
(RSVHR Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've taken certain antiviral, antibacterial, antifungal, or antimycobacterial medications within 7 days before joining. It's best to discuss your current medications with the trial team.
What is the purpose of this trial?
This trial tests an oral medication called EDP-938 for adults with RSV who are at high risk of severe illness. The goal is to help fight the virus or reduce its impact.
Research Team
Enanta Pharmaceuticals, Inc
Principal Investigator
Enanta Pharmaceuticals, Inc
Eligibility Criteria
Adults over 65 or those with heart failure, asthma, COPD at high risk for RSV complications can join. They must have recent respiratory symptoms and a positive RSV test. Participants need to use contraception if of childbearing potential. Exclusions include recent COVID-19 infection, severe lung function impairment, certain heart conditions, living in care facilities receiving acute respiratory management, imminent hospitalization need, recent systemic anti-infective therapy or active viral hepatitis/HIV.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive EDP-938 or placebo orally once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- EDP-938
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Enanta Pharmaceuticals, Inc
Lead Sponsor